PROQR THERAPEUTICS EO-04 Cash Flow Conversion Efficiency
PROQR THERAPEUTICS EO-04 cash flow conversion efficiency. Based on the latest financial reports, PROQR THERAPEUTICS EO-04 (0PQ) has a cash flow conversion efficiency ratio of -0.271x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-13.36 Million ≈ $-15.62 Million USD) by net assets (€49.37 Million ≈ $57.72 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PROQR THERAPEUTICS EO-04 (2021–2025)
Cash flow conversion efficiency of PROQR THERAPEUTICS EO-04 from 2021 to 2025. This chart illustrates how PROQR THERAPEUTICS EO-04's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PROQR THERAPEUTICS EO-04 (0PQ) share price today for real-time trading data and today's change.
PROQR THERAPEUTICS EO-04 Cash Flow Conversion Ratio Explained
PROQR THERAPEUTICS EO-04 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PROQR THERAPEUTICS EO-04 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PROQR THERAPEUTICS EO-04 ranked by their cash flow conversion efficiency. Also see market value of PROQR THERAPEUTICS EO-04 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HIM International Music
TWO:8446
|
0.018x |
|
GDB Holdings Bhd
KLSE:0198
|
0.267x |
|
Sai Gon Cargo Service Corp
VN:SCS
|
0.091x |
|
Yayla Agro Gida Sanayi ve Ticaret A.S.
IS:YYLGD
|
0.339x |
|
Biomm S.A
SA:BIOM3
|
-0.164x |
|
Thong Guan Industries Bhd
KLSE:7034
|
0.049x |
|
Dexxos Participações S.A
SA:DEXP3
|
0.115x |
|
Satellos Bioscience Inc. Common Stock
NASDAQ:MSLE
|
-0.131x |
Annual Cash Flow Conversion Efficiency for PROQR THERAPEUTICS EO-04 (2021–2025)
The table below shows the annual cash flow conversion efficiency of PROQR THERAPEUTICS EO-04 from 2021 to 2025. Review how much free cash does PROQR THERAPEUTICS EO-04 generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €49.37 Million ≈ $57.72 Million |
€-52.79 Million ≈ $-61.72 Million |
-1.069x | -160.18% |
| 2024-12-31 | €88.56 Million ≈ $103.54 Million |
€-36.39 Million ≈ $-42.55 Million |
-0.411x | -178.93% |
| 2023-12-31 | €41.39 Million ≈ $48.39 Million |
€21.55 Million ≈ $25.19 Million |
0.521x | +150.67% |
| 2022-12-31 | €66.68 Million ≈ $77.96 Million |
€-68.51 Million ≈ $-80.09 Million |
-1.027x | -347.22% |
| 2021-12-31 | €113.23 Million ≈ $132.38 Million |
€-26.01 Million ≈ $-30.41 Million |
-0.230x | -- |
About PROQR THERAPEUTICS EO-04
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic disea… Read more